All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F21%3A10428906" target="_blank" >RIV/00216208:11110/21:10428906 - isvavai.cz</a>

  • Alternative codes found

    RIV/65269705:_____/21:00074416 RIV/00064165:_____/21:10428906

  • Result on the web

    <a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=3N5ObQcAux" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=3N5ObQcAux</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1038/s41408-021-00478-4" target="_blank" >10.1038/s41408-021-00478-4</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

  • Original language description

    The use of novel therapies, such as immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and monoclonal antibodies (mAbs; ie, isatuximab, daratumumab, elotuzumab), has significantly improved the outcomes of multiple myeloma (MM) patients. However, MM remains largely incurable, with the majority of patients becoming refractory to available therapies and eventually relapsing.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30205 - Hematology

Result continuities

  • Project

  • Continuities

    V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Others

  • Publication year

    2021

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Blood Cancer Journal

  • ISSN

    2044-5385

  • e-ISSN

  • Volume of the periodical

    11

  • Issue of the periodical within the volume

    5

  • Country of publishing house

    GB - UNITED KINGDOM

  • Number of pages

    5

  • Pages from-to

    89

  • UT code for WoS article

    000649709100001

  • EID of the result in the Scopus database

    2-s2.0-85105788793